ELTX · NASDAQ
Elicio Therapeutics (ELTX) Stock Price & Fundamentals
Elicio Therapeutics (ELTX) closed at $921.73 on Oct 9, 2026, up 1.83% from the previous close of $905.16.
Share price, past year
1Y +29.40%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $921.73 |
| Sep 30, 2026 | $958.85 |
| Aug 31, 2026 | $1,022.44 |
| Jul 31, 2026 | $1,028.01 |
| Jun 30, 2026 | $946.72 |
| May 29, 2026 | $915.46 |
| Apr 30, 2026 | $933.91 |
| Mar 31, 2026 | $875.92 |
| Feb 27, 2026 | $815.45 |
| Jan 30, 2026 | $838.48 |
| Dec 31, 2025 | $801.10 |
| Nov 28, 2025 | $752.39 |
| Oct 31, 2025 | $698.81 |
Key statistics
- Market cap
- $20.19B
- P/E (TTM)
- —
- EPS (TTM)
- −$2.13
- Revenue (TTM)
- —
- Net income (TTM)
- −$37.84M
- Shares outstanding
- 21.9M
- Dividend yield
- —
- 52-week range
- $690.23 – $1,046.23
Elicio Therapeutics's market cap is $20.19B, based on a share price of $921.73 and 21.9M shares outstanding as of Jun 30, 2026.
Financials
Elicio Therapeutics reported revenue of $2.30M for fiscal 2022, down 91.87% from fiscal 2021.
Elicio Therapeutics reported a net loss of $39.57M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2022ended Dec 31, 2022 | $2.30M | −91.9% | −$28.21M | −1,225.9% | −$89.27 | −$22.83M |
| FY2021ended Dec 31, 2021 | $28.31M | +883.1% | −$54.57M | −192.8% | −$1.93 | −$53.03M |
| FY2020ended Dec 31, 2020 | $2.88M | — | −$80.11M | −2,781.5% | −$5.43 | −$22.93M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2023ended Mar 31, 2023 | $0.00 | — | — |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $0.00 | — | — |
| Q2 FY2022ended Jun 30, 2022 | $653.00K | — | — |
| Q1 FY2022ended Mar 31, 2022 | $1.65M | — | — |
| Q4 FY2021ended Dec 31, 2021 | $25.94M | — | — |
| Q3 FY2021ended Sep 30, 2021 | $1.46M | — | — |
| Q2 FY2021ended Jun 30, 2021 | $540.00K | — | — |
Company profile
- Name
- Elicio Therapeutics, Inc.
- Ticker
- ELTX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 451 D Street, 5th Floor, Boston, MA 02210
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001601485
Recent SEC filings
- Sep 14, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jul 2, 2026
- Jun 24, 2026
- Jun 17, 2026
- Jun 15, 2026
- May 11, 2026
Frequently asked questions
What is Elicio Therapeutics's stock price?
Elicio Therapeutics (ELTX) closed at $921.73 on Oct 9, 2026, up 1.83% from the previous close of $905.16.
What is Elicio Therapeutics's market cap?
Elicio Therapeutics's market cap is $20.19B, based on a share price of $921.73 and 21.9M shares outstanding as of Jun 30, 2026.
How much revenue does Elicio Therapeutics make?
Elicio Therapeutics reported revenue of $2.30M for fiscal 2022, down 91.87% from fiscal 2021.
Does Elicio Therapeutics pay a dividend?
Elicio Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Elicio Therapeutics, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures